Recombinant Human Elongation of very long chain fatty acids protein 4 (ELOVL4)

What is the molecular structure of ELOVL4 and how does it relate to its enzymatic function?

ELOVL4 is a transmembrane protein located in the endoplasmic reticulum with a predicted molecular weight of 36.8 kDa containing 314 amino acids . Research suggests two possible topological models for ELOVL4:

• A five transmembrane-spanning topology

• A seven transmembrane-spanning topology

The protein contains critical functional domains:

• A catalytic histidine core essential for enzymatic activity

• An ER retention/retrieval signal (KXKXX) at the C-terminus required for localization

• N-glycosylation consensus motifs that do not affect enzymatic function

Methodological approach: To study ELOVL4 structure-function relationships, researchers should use site-directed mutagenesis targeting the histidine core and ER retention signal, followed by activity assays and subcellular localization studies. Expression systems should maintain the protein within the ER membrane to preserve enzymatic function.

Which fatty acid substrates does ELOVL4 specifically elongate?

ELOVL4 demonstrates specific substrate selectivity:

Unlike other elongases, ELOVL4 specifically catalyzes the elongation of:

• 20:5n3 (eicosapentaenoic acid, EPA) and 22:5n3 (docosapentaenoic acid, DPA) to VLC-PUFA with chain lengths ≥28 carbons

• 26:0 to VLC-SFA (28:0, 30:0, and longer)

Notably, ELOVL4 does not participate in DHA (22:6n3) biosynthesis , which has significant implications for therapeutic approaches to ELOVL4-related disorders.

Methodological approach: For substrate specificity studies, use recombinant ELOVL4 expression systems combined with LC-MS/MS analysis of elongation products. EPA is preferred over AA (20:4n6) and DHA as a substrate for VLC-PUFA formation .

How does ELOVL4 expression differ across tissues, and what methods are most effective for studying tissue-specific functions?

ELOVL4 demonstrates distinct tissue-specific expression patterns correlating with unique fatty acid profiles:

In the retina, ELOVL4 is highly enriched in rod and cone photoreceptors, specifically concentrated in photoreceptor inner segments . This tissue-specific localization corresponds with the high levels of VLC-PUFA-containing glycerophospholipids in the retina .

Methodological approach: For tissue-specific functional studies, researchers should:

• Generate tissue-specific conditional knockout models (e.g., photoreceptor-specific Elovl4 knockout mice )

• Use high-performance liquid chromatography-mass spectrometry (HPLC-MS) to analyze fatty acid composition of membrane glycerophospholipids

• Combine histological, immunofluorescent, and electrophysiological assessments to correlate structural and functional changes

What are the specific functions of VLC-PUFA and VLC-SFA in different tissues?

The tissue-specific functions of ELOVL4 products demonstrate their essential roles:

VLC-PUFA Functions:

• Retina: Essential for retinal function through formation of bioactive "Elovanoids"

• Sperm: Critical for fertility and sperm function

VLC-SFA Functions:

• Brain: Enriched in synaptic vesicles where they mediate neuronal signaling by determining neurotransmitter release rates

• Skin: Maintain permeability barrier function through specialized lipid structures

Methodological approach: To investigate tissue-specific functions, researchers should employ:

• Lipidomic profiling using LC-MS/MS to characterize VLC-FA distributions

• Electrophysiology to assess synaptic function in VLC-SFA-enriched neurons

• Barrier function assays in skin models lacking VLC-SFA

What is the catalytic mechanism of ELOVL4 in fatty acid elongation?

ELOVL4 catalyzes the initial, rate-limiting condensation reaction in the four-step fatty acid elongation cycle:

• Condensation: ELOVL4 catalyzes the condensation between an acyl-CoA and malonyl-CoA, producing a 3-ketoacyl-CoA (rate-limiting step)

• Reduction: 3-ketoacyl-CoA reductase (KAR) reduces the ketone group

• Dehydration: 3-hydroxyacyl-CoA dehydratases (HACD1-4) remove water

• Reduction: Trans-2,3-enoyl-CoA reductase (TER) performs the final reduction

The elongation proceeds via an acyl-enzyme intermediate involving the second histidine in the canonical HxxHH motif, as demonstrated for the ELOVL family .

Methodological approach: To study the catalytic mechanism:

• Perform site-directed mutagenesis of the conserved histidine residues in the HxxHH motif

• Use cell-free microsomal assays to assess enzymatic activity

• Employ radiolabeled substrates to track intermediates in the elongation process

How do ELOVL4 protein-protein interactions affect its enzymatic activity?

ELOVL4 forms both homo-oligomeric and hetero-oligomeric complexes that significantly impact its function:

• Homodimers: ELOVL4 can form homodimers; mutant and wild-type ELOVL4 dimerization leads to mislocalization away from the ER

• Hetero-oligomers: ELOVL4 can complex with other ELOVL family members and VLC-FA-associated enzymes

• Dominant negative effects: Mutant ELOVL4 forms interact more strongly with other elongases and enzymes than wild-type ELOVL4, potentially affecting synthesis of multiple fatty acid species

Methodological approach: To investigate protein-protein interactions:

• Use co-immunoprecipitation and proximity ligation assays to detect interacting partners

• Employ bimolecular fluorescence complementation to visualize interactions in living cells

• Assess enzymatic activity in reconstituted systems with purified components

How do different ELOVL4 mutations lead to distinct tissue-specific pathologies?

Different mutations in the ELOVL4 gene cause remarkably distinct tissue-specific disorders:

The W246G mutation shows dramatically impaired VLC-SFA synthesis with partially preserved VLC-PUFA synthesis, while L168F exhibits a gain of function in certain VLC-PUFA species (38:5n3) but reduced VLC-SFA production .

Methodological approach: To study mutation-specific effects:

• Generate cell models expressing specific ELOVL4 mutations using CRISPR/Cas9

• Compare lipidomic profiles across mutation types

• Assess protein localization using immunofluorescence

• Measure enzymatic activity for both VLC-PUFA and VLC-SFA synthesis

What are the cellular consequences of ELOVL4 mutations in photoreceptors?

The cellular pathology in STGD3 involves multiple mechanisms:

• Protein mislocalization: Truncated ELOVL4 lacking the ER retention signal is mislocalized from the ER to Golgi in photoreceptors

• Aggregate formation: Mutant ELOVL4 forms aggregates in the endoplasmic reticulum of photoreceptors

• Dominant negative effects: Mutant ELOVL4 downregulates wild-type ELOVL4 function, reducing VLC-PUFA synthesis

• Enzymatic inactivity: The 5-bp deletion mutant ELOVL4 lacks all innate condensation activity

• VLC-PUFA depletion: Progressive loss of retinal VLC-PUFA contributes to photoreceptor degeneration

Methodological approach: To investigate cellular consequences:

• Use photoreceptor-specific conditional knockout models

• Perform electron microscopy to visualize ultrastructural changes

• Employ live cell imaging to track protein aggregation

• Use electrophysiology to assess functional changes preceding cell death

How can recombinant ELOVL4 be optimally expressed and purified for in vitro studies?

Expressing functional ELOVL4 presents unique challenges due to its transmembrane nature:

Expression system optimization:

• Recombinant adenovirus approach: Use recombinant adenovirus type 5 viral particles carrying the mouse Elovl4 minigene for expression in model cell lines such as ARPE-19 cells

• Membrane protein considerations: ELOVL4 requires proper ER membrane integration for activity; detergent selection is critical during purification

• Functional assessment: Validate activity using microsomal assays with radiolabeled substrates

Methodological approach: A comprehensive protocol should include:

• Clone human ELOVL4 cDNA into expression vectors with appropriate tags

• Express in eukaryotic systems that maintain ER structure (HEK293, CHO, ARPE-19 cells)

• Prepare microsomes for functional studies rather than attempting complete purification

• Validate using LC-MS/MS detection of elongation products

What experimental approaches can distinguish between VLC-PUFA and VLC-SFA production in different tissue contexts?

Differential analysis of VLC-PUFA and VLC-SFA production requires sophisticated methodologies:

Analytical approaches:

• HPLC-MS techniques: High-performance liquid chromatography coupled with mass spectrometry allows specific identification of VLC-PUFA and VLC-SFA species

• Tissue-specific isotope labeling: Use tissue-specific expression of mutant ELOVL4 variants with differential activity (e.g., W246G which selectively impairs VLC-SFA synthesis)

• Substrate manipulation: Supply specific precursors (EPA vs. 26:0) to analyze pathway-specific outputs

Methodological approach:

• Extract total lipids using modified Bligh and Dyer methods

• Perform fatty acid methyl ester (FAME) derivatization

• Use LC-MS/MS with multiple reaction monitoring for chain length and saturation specificity

• Incorporate internal standards for absolute quantification

How do ELOVL4-derived VLC-PUFAs and VLC-SFAs specifically influence synaptic function?

Recent research reveals distinct mechanisms for VLC-PUFA and VLC-SFA in synaptic function:

VLC-PUFA in retinal synapses:

• Form bioactive "Elovanoids" that promote photoreceptor and retinal pigment epithelium cell survival

• Contribute to specialized membrane microdomains in photoreceptor terminals

VLC-SFA in brain synapses:

• Enriched in synaptic vesicles

• Regulate neurotransmitter release rate

• Affect synaptic vesicle fusion kinetics through membrane biophysical properties

Methodological approach: To investigate synaptic functions:

• Use electrophysiology to measure synaptic transmission in tissue-specific Elovl4 knockout models

• Perform electron microscopy to assess synaptic vesicle morphology and distribution

• Use optical methods (SynaptoZip, SynTagMA) to monitor vesicle fusion events in real-time

• Employ lipidomic analysis of isolated synaptic vesicle fractions

What strategies might restore ELOVL4 function or compensate for its loss in disease states?

Potential therapeutic approaches targeting ELOVL4-related disorders include:

• Gene therapy approaches:

  • AAV-mediated delivery of wild-type ELOVL4 to affected tissues

  • CRISPR/Cas9-based correction of specific mutations

• Small molecule screening:

  • Compounds that promote proper folding and localization of mutant ELOVL4

  • Drugs that enhance remaining ELOVL4 activity in heterozygous conditions

• Dietary supplementation strategies:

  • Direct supplementation with VLC-PUFA or VLC-SFA (limited by blood-brain/retinal barriers)

  • Note: DHA supplementation alone is ineffective for STGD3, as clinical trials (650 mg EPA + 350 mg DHA daily) did not attenuate maculopathy progression

Methodological approach: To develop therapeutic strategies:

• Test gene therapy constructs in animal models of ELOVL4-related diseases

• Develop high-throughput screens for compounds that rescue mutant ELOVL4 localization

• Explore nanoparticle-based delivery of synthetic VLC-PUFAs/VLC-SFAs

How might manipulation of ELOVL4 activity impact broader metabolic pathways?

Modulating ELOVL4 activity could have extensive metabolic consequences:

• Intersection with other elongase pathways:

  • Given ELOVL4's interactions with other elongases, its manipulation may affect broad lipid metabolism

  • ELOVL4 inhibition affects AMP-activated protein kinase (AMPK) signaling

• Oxidative stress responses:

  • ELOVL4 inhibition leads to reactive oxygen species (ROS) production

  • Altered ELOVL4 activity influences the unfolded protein response (UPR)

• Transcriptional regulation:

  • ELOVL4 inhibition robustly induces Krüppel-like factor 4 (KLF4) expression

  • KLF4 acts as a downstream target of AMPK in regulating vascular smooth muscle cell phenotype

Methodological approach: To investigate metabolic consequences:

• Perform RNA-seq analysis on tissues with modulated ELOVL4 activity

• Use metabolomics to assess broader lipid metabolism changes

• Analyze signaling pathway activation with phospho-specific antibodies

• Investigate transcription factor binding using ChIP-seq